JAZZ PHARMACEUTICALS FRANCE

Axsome Therapeutics, a mid-cap biotech, focuses on CNS diseases with two marketed products: Auvelity for depression and Sunosi for narcolepsy. Despite being unprofitable, its revenue grew 87% YoY in Q2, driven by Auvelity's 135% sales increase. Axsome's pipeline includes potential approvals for migraines, Alzheimer's agitation, ADHD, shift work disorder, and fibromyalgia, suggesting future growth and stock price potential.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

Douglas B. Snyder joins IDEAYA Biosciences as SVP, General Counsel, bringing over 25 years of legal experience from GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDA.

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.

The North America Clozapine Tablet market, driven by tech advancements and data-driven decisions, is segmented by applications like schizophrenia, bipolar disorder, resistant depression, and psychotic disorders. Key manufacturers include Mylan, Novartis, and Teva Pharmaceuticals. The market's future is promising, with strategic adaptation to emerging trends crucial for growth.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

ALX Oncology Holdings Inc. develops Evorpacept [ALX148], a first-in-class CD47 inhibitor with an inactive Fc domain reducing side effects. ASPEN-06 Phase 2 trials combining Evorpacept with trastuzumab, ramucirumab, and paclitaxel (TRP) showed favorable results in HER2-positive gastric and gastroesophageal junction (GEJ) cancer. Evorpacept has FDA Fast Track designations for several indications, making the shares potentially bullish.

The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 report details the growing exosome market, highlighting advancements in diagnostics, therapeutics, and cosmetics. Exosomes, extracellular vesicles, are valuable for disease detection, diagnosis, and treatment. The market is expanding with 388 clinical trials underway, and first exosome therapeutics expected by 2029. Key players and technologies are profiled, along with market forecasts through 2030.

Jazz Pharmaceuticals to present five abstracts at ESMO Congress 2024, including new data on zanidatamab for HER2-positive mGEA and mCRC, and Zepzelca for relapsed SCLC.